

LSU Health Science Center

LSU Health Digital Scholar

Medical Research Day

2022 Medical Research Day Posters

Oct 13th, 12:00 AM

The Effects of Obesity and Estrogen Based Contraceptive Use on Protein S Levels and Clotting Function in Pre-menopausal Women

Daniel Ruppert

LSU Health Sciences Center- New Orleans

Alaa Malik

LSU Health Sciences Center- New Orleans, amali5@lsuhsc.edu

Manoj Kumar

LSU Health Sciences Center- New Orleans

Rinku Majumder

LSU Health Sciences Center- New Orleans, rmajum@lsuhsc.edu

Follow this and additional works at: <https://digitalscholar.lsuhscc.edu/sommrd>



Part of the [Medical Biochemistry Commons](#)

Recommended Citation

Ruppert, Daniel; Malik, Alaa; Kumar, Manoj; and Majumder, Rinku, "The Effects of Obesity and Estrogen Based Contraceptive Use on Protein S Levels and Clotting Function in Pre-menopausal Women" (2022). *Medical Research Day*. 73.


<https://digitalscholar.lsuhscc.edu/sommrd/2022MRD/Posters/73>

This Event is brought to you for free and open access by the School of Medicine at LSU Health Digital Scholar. It has been accepted for inclusion in Medical Research Day by an authorized administrator of LSU Health Digital Scholar. For more information, please contact aolini@lsuhsc.edu.

Introduction

Protein S (PS) is an essential natural anticoagulant whose deficiency is a major contributor to acquired hypercoagulability [1]. Acquired hypercoagulability causes myocardial infarction, stroke, and deep vein thrombosis in millions of individuals [2]. Many factors affect plasma PS level; most prominently, the female hormone estrogen alters PS level by suppressing PS gene transcription via the estrogen receptor α (ER α) [3]. Thus, women who use estrogen-based oral contraceptive agents (OCA) experience a decrease in PS level. This contraceptive-induced PS decrease enhances the risk of thrombosis by 3-fold [4]. Decreased plasma PS is also associated with obesity; obesity elevates the risk of thrombosis by 2.5-fold [5]. Dramatically, the risk of thrombosis increases as much as 24-fold in obese subjects who use OCA [6]. This study is aimed to determine whether there is a downregulation of PS in premenopausal obese women on estrogen-based contraceptives compared to the controls.

Methods



Results

aPTT, TGA, and ELISA Assays




Figure 1: Clotting function tests results; (A) aPTT, (B) ELISA, (C) TGA, (D) TGA modified with added PS.

Western Blot Assay




Figure 2: Immunoblot results; (A) Protein S bands, (B) Transferrin Control bands, (C) graphic results of band intensities based on volunteer group.

Conclusion

- Individuals who were considered obese, had OCA use, or both had a shorter aPTT clotting times and higher thrombin generations compared to controls.
- Free PS levels were measured by ELISA and observed that free PS levels of the subjects on OCA are significantly lower than controls
- Total PS levels in OCA, obese, and obese + OCA samples are significantly lower compared to the controls.
- Overall, the use of OCA and obesity contribute to hypercoagulability due to shorter clotting times, low free and total PS levels, and high thrombin generation.

Future Perspectives

- More participants are needed to provide a more representative sample.
- Determine if the binding protein of protein S, C4b, contributes to differences in Free and Total PS.

References

- Schwarz, H.P., et al., Plasma protein S deficiency in familial thrombotic disease. *Blood*, 1984, 64(6): p.1297-300.
- Spencer, F.A., et al., The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. *J Gen Intern Med*, 2006, 21(7): p. 722-7.
- Suzuki, A., et al., Down-regulation of PROS1 gene expression by 17 β estradiol via estrogen receptor α (ER α)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. *J Biol Chem*, 2010, 285(18): p. 13444-53.
- Piparva, Kiran S., and Jatin G. Buch. "Deep Vein Thrombosis in a Woman Taking Oral Combined Contraceptive Pills." *Journal of Pharmacology and Therapeutics*, vol. 2, no. 3, 2011, pp. 185-186. <https://doi.org/10.4103/0976-500x.83284>.
- Abdollahi, M., M. Cushman, and F.R. Rosendaal. Obesity, risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. *Thromb Haemostasis*, 2003, 89(3): p. 483-8.
- Pomp, E.R., et al., Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutation.